ERP System Validation in Pharma: The Complete GxP Guide (2026)

What does ERP system validation actually require in a pharma GxP environment, and what do most teams get wrong?

ERP validation requires qualifying GxP-critical configurations (batch releases, quality workflows, and audit trails) while using vendor evidence for the core system. Most teams fail by over-validating non-GxP modules like finance or failing to manage system changes after go-live.

Most ERP validation programmes are credible at go-live and gradually eroded afterward by uncontrolled change. This guide covers how to establish a clean validation baseline and maintain compliance post go-live.

The GAMP 5 Classification Decision and Why It Matters

SAP S/4HANA, Oracle Fusion, and Microsoft Dynamics 365 are GAMP 5 Second Edition Category 4: configured commercial software. That means three things in practice.

First: the base platform is treated as vendor-qualified — you reference vendor evidence (SAP's VSP, Oracle's CQP) instead of re-testing standard functionality.

Second: every GxP-critical configuration you apply on top — a batch workflow, a deviation routing rule — is your responsibility to test, not the vendor's.

Third, and most often missed: custom ABAP, extensions, or code are Category 5, requiring full SDLC documentation. Teams routinely underestimate how much Category 5 code an implementation actually produces.

The Scope Decision: Which Modules Are GxP-Critical

Scope is the most consequential decision in ERP validation. Too broad, and you spend a year testing accounts payable screens. Too narrow, and you miss the batch management integration an inspector asks for on day one.

ERP Module / Function	Scope	Reasoning
Batch management / e-batch records	Always In	Direct impact on batch release — highest GxP risk in the ERP
Quality management (deviations, CAPA)	Always In	21 CFR 211 / EU Annex 11 — failure affects patient safety
E-signatures and audit trails	Always In	21 CFR Part 11 applies to every GxP record
Goods receipt / release, sampling	Always In	Controls raw material release upstream of manufacturing
Warehouse (quarantine, temp zones)	Always In	GDP/GMP requirement for controlled stock
Serialization / track and trace	Always In	Regulatory mandate — production-to-dispenser traceability
Master data — material master, BOMs	Context Dependent	In scope if it governs production or quality decisions
Procurement / purchase orders	Context Dependent	In scope only where it triggers a GxP activity
Finance / accounts payable / payroll	Typically Out	No product quality or patient safety impact
HR administration	Typically Out	Out of scope unless it holds GxP training records

The master data trap: A GxP material master record is itself a GxP record under 21 CFR 211. Changes to it must go through documented change control regardless of whether the module was formally in scope — this is one of the most common 483 findings in ERP environments.

What IQ, OQ, and PQ Actually Mean for an ERP

These phases are commonly misapplied to ERP because teams borrow protocols from single-application validations without adapting them to a system with hundreds of modules and complex integrations.

Phase 1

Installation Qualification

"Is this ERP correctly installed in its intended environment?"

Mostly infrastructure: servers, database, network, backups. For cloud ERP, get documented vendor evidence the hosted environment meets spec — don't just take their word for it.

Phase 2

Operational Qualification

"Does every GxP-critical configured function perform as specified?"

The heaviest phase. Covers batch workflows, signature enforcement, audit trails, and CAPA routing. Common mistake: testing individual screens instead of complete workflow paths — an inspector traces the full chain, and so should your OQ.

Phase 3

Performance Qualification

"Does the ERP support real GxP processes with real users?"

Most underspecified phase. Design PQ around end-to-end scenarios — goods receipt through dispatch — not isolated function tests, and include realistic concurrent-user load and LIMS/MES integration handshakes.

The Real Validation Problem: Post Go-Live Drift

Post go-live drift is the gradual accumulation of small modifications that separate the production system from its originally validated baseline. This standard compliance erosion generally stems from four specific areas:

Vendor updates without GxP impact assessment: Software patches and technical hotfixes are often applied by IT automatically, changing core system behaviors without updating validation documentation.
Configuration changes directly in production: Urgent process adjustments—such as changing deviation routing paths or editing field mandatory states—are frequently done live, creating a silent mismatch with the validation records.
Business process shifts outpacing validation: New product types, newly added facilities, or process realignments roll out into production before the validation team can record or test the structural workflow impact.
Unassessed integration changes: API contracts, system connections, or third-party middleware endpoints (like an upgraded LIMS or MES interface) change without verifying data integrity boundaries.

ERP Upgrade Validation: The Decision Framework

Upgrading an ERP — from SAP ECC to S/4HANA, from Oracle 12 to Oracle Fusion Cloud, or from one Dynamics major release to another — is one of the highest-risk validation events a pharma team faces. The most important insight is this: an ERP upgrade is not a new system validation. It is a change to a validated system, and the validation scope should be determined by what the upgrade actually changes, not by the size of the project.

Change Type	Revalidation Scope	What Most Teams Get Wrong
Minor support package (UI / bug fixes only)	Impact assessment + targeted retesting of affected functions only	Either skip assessment entirely, or repeat full OQ "to be safe" — both are wrong
Major functional release (new modules, changed logic)	Full OQ of all changed GxP-critical functions; PQ for affected end-to-end processes	Treating it like a support package — scoping retesting only to changed screens rather than downstream process impacts
Platform migration (ECC to S/4HANA)	Full re-execution of OQ and PQ for all GxP-critical functions — the underlying data model and logic may have fundamentally changed	Accepting vendor migration documentation as equivalent to site-specific qualification — vendor documentation covers standard functionality, not your configurations
Cloud migration (on-prem to hosted)	Full IQ for the new environment + impact assessment on all GxP functions + PQ on end-to-end processes	Treating infrastructure change as non-validation-relevant because "the application didn't change" — the hosting environment is part of the validated system

Applying FDA CSA to ERP: Where It Helps and Where It Doesn't

FDA's Computer Software Assurance (CSA) guidance permits a risk-proportionate approach to testing, allowing teams to accept vendor documentation for the underlying ERP platform. However, it does not reduce the need for testing custom configurations that drive GxP workflows.

CSA Reduces Effort Here

Low-risk configured functions

Standard reports, dashboards, internal administrative workflows, and non-GxP operational screens can leverage unscripted testing and basic vendor testing packages to streamline documentation.

CSA Does Not Reduce Effort Here

High-risk GxP-critical functions

Core workflows like electronic signature enforcement, audit trail captures, batch release parameters, and serialization must be verified with full scripted testing specific to the company's installation.

What FDA Inspectors Actually Ask For

During regulatory audits, FDA inspectors typically target three key elements of an ERP architecture:

Audit trail integrity: Documented proof that system records cannot be altered, disabled, or deleted, showing a chronological timeline of user actions from batch creation to final sign-off.
Master data change controls: Verification that access rights to recipes, bills of materials (BOMs), and specification limits are locked down under formal GMP change parameters rather than basic IT permissions.
Periodic review status: Evidence demonstrating that the active system configuration matches the original validated design baseline, validating that post go-live updates have not introduced compliance gaps.

Where GoVal Fits in ERP Validation

GoVal manages the validation lifecycle of your ERP system — and every other GxP system in your environment — in a single platform. The ERP's validated baseline is maintained as a live record: configuration snapshot, test evidence, RTM linking requirements to executed tests, deviations, and change history. When a vendor update requires impact assessment, that assessment is a structured workflow in GoVal with a documented conclusion — not a free-text email that may or may not end up in the right folder. When periodic review is due, GoVal triggers it and tracks the current configuration against the validated baseline, flagging gaps before an inspector does.

Frequently Asked Questions

What GAMP 5 category is an ERP system in pharma? +

A configured commercial ERP system — SAP, Oracle, Microsoft Dynamics 365 — is GAMP 5 Category 4: configured commercial software. The base ERP platform is treated as vendor-qualified, and the pharma company validates the GxP-critical configurations on top. Category 4 does not mean validation is light — it means vendor evidence can be accepted for base platform functionality, while full testing is required for all GxP-critical configured functions: batch management, quality workflows, electronic signatures, audit trails, and any custom reports or interfaces. Custom code (ABAP, extensions) is Category 5 and requires full SDLC documentation.

Which ERP modules need to be validated in a GxP pharma environment? +

GxP-critical ERP modules are those whose failure or malfunction could directly affect product quality, patient safety, or data integrity. Always in scope: batch management and electronic batch records, quality management (deviations, CAPA, complaints), goods receipt and release with sampling controls, warehouse management for temperature-controlled and quarantine stock, serialization and traceability, electronic signatures, and audit trails. Typically out of scope: accounts payable, payroll, HR administration, and general ledger — unless they contain data feeding a GxP decision. Scope exclusions must be documented with rationale in the functional risk assessment.

How do you validate SAP S/4HANA for pharma GxP compliance? +

SAP S/4HANA validation follows the GAMP 5 Category 4 approach: SAP's standard software is treated as vendor-qualified using SAP's Validation Support Package (VSP), and the validation effort focuses on GxP-critical configured functions. A functional risk assessment identifies which configured functions affect product quality or patient safety — these become the OQ and PQ scope. Any custom ABAP development is Category 5 and requires full SDLC documentation. For cloud-hosted S/4HANA (SAP RISE), the hosting infrastructure qualification relies on SAP-provided evidence — but configuration testing remains the customer's responsibility.

What is the scope of IQ, OQ, and PQ for an ERP system? +

IQ for ERP confirms the system is correctly installed in its environment — server, database, network, security, and access controls. OQ tests GxP-critical configured functions: batch workflow execution, quality inspection routing, electronic signature enforcement, audit trail capture, deviation creation and routing. PQ confirms end-to-end process execution in the production environment under realistic conditions — complete business processes (goods receipt through batch release) executed by actual users. PQ scope is commonly underspecified because it is designed against individual functions rather than end-to-end process chains that reflect how inspectors trace compliance.

What happens to ERP validation when SAP or Oracle pushes a vendor update? +

Every vendor update must be assessed through change control for GxP impact before being applied to the validated system. The assessment must determine whether the update touches any GxP-critical function — audit trail behaviour, electronic signature logic, batch processing. If yes, partial requalification of affected functions is required before promotion to production. For cloud ERP where the vendor controls update timing, the organisation must negotiate notification windows that allow impact assessment before deployment — or maintain a pre-production environment specifically for validation pre-assessment.

Can FDA's CSA guidance reduce ERP validation effort? +

Yes, selectively. FDA's Computer Software Assurance guidance (September 2025) reduces effort for lower-risk configured functions — dashboards, non-GxP reports, financial workflows — where vendor evidence and documented risk rationale replace scripted testing. It does not reduce validation effort for high-risk GxP-critical ERP functions like batch release logic, electronic signature enforcement, or audit trail controls. The practical benefit is proportionate scope: stop testing low-risk financial screens and redirect effort to thoroughly testing batch management and quality workflows where failure actually matters.

Manage your ERP validation lifecycle — from baseline to periodic review

Live RTM, change control, post go-live drift tracking, and inspection-ready evidence — in GoVal.

Book a Free Demo →